Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 22  •  04:00PM ET
10.03
Dollar change
-0.14
Percentage change
-1.38
%
Index
RUT
P/E
-
EPS (ttm)
-1.43
Insider Own
28.09%
Shs Outstand
81.12M
Perf Week
-10.84%
Market Cap
928.35M
Forward P/E
-
EPS next Y
-1.75
Insider Trans
-0.56%
Shs Float
66.56M
Perf Month
31.11%
Enterprise Value
951.11M
PEG
-
EPS next Q
-0.61
Inst Own
50.23%
Perf Quarter
31.45%
Income
-114.20M
P/S
11.41
EPS this Y
-70.42%
Inst Trans
1.11%
Perf Half Y
21.72%
Sales
81.39M
P/B
-
EPS next Y
27.69%
ROA
-43.86%
Perf YTD
26.16%
Book/sh
-0.07
P/C
14.08
EPS next 5Y
-10.19%
ROE
-368.19%
52W High
11.85 -15.36%
Perf Year
59.97%
Cash/sh
0.71
P/FCF
-
EPS past 3/5Y
20.90% 1.58%
ROIC
-206.30%
52W Low
4.55 120.44%
Perf 3Y
76.90%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
72.27% 39.22%
Gross Margin
78.64%
Volatility
8.55% 8.07%
Perf 5Y
-28.66%
Dividend TTM
-
EV/Sales
11.69
EPS Y/Y TTM
32.96%
Oper. Margin
-131.92%
ATR (14)
0.76
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
0.75
Sales Y/Y TTM
144.57%
Profit Margin
-140.31%
RSI (14)
57.74
Dividend Gr. 3/5Y
- -
Current Ratio
0.75
EPS Q/Q
137.01%
SMA20
7.26%
Beta
1.33
Payout
-
Debt/Eq
-
Sales Q/Q
252.33%
SMA50
21.74%
Rel Volume
1.60
Prev Close
10.17
Employees
403
LT Debt/Eq
-
SMA200
23.80%
Avg Volume
630.79K
Price
10.03
IPO
Jun 08, 2018
Option/Short
Yes / Yes
Trades
Volume
994,272
Change
-1.38%
Date Action Analyst Rating Change Price Target Change
Nov-24-25Initiated H.C. Wainwright Buy $20
Oct-21-25Initiated Raymond James Strong Buy $29
Jul-31-24Resumed Chardan Capital Markets Buy $36
Oct-23-20Initiated RBC Capital Mkts Outperform $27
Sep-15-20Resumed BofA Securities Buy $20
Sep-03-19Initiated Piper Jaffray Overweight $40
Feb-27-19Reiterated Chardan Capital Markets Buy $30 → $40
Jul-03-18Initiated BofA/Merrill Buy
Jul-03-18Initiated Barclays Overweight
Apr-16-26 07:47AM
07:10AM
07:00AM
Apr-14-26 08:30AM
Mar-26-26 08:00AM
08:15AM Loading…
Mar-09-26 08:15AM
Mar-05-26 08:25AM
Mar-03-26 05:35PM
Feb-26-26 09:55AM
Feb-03-26 08:00AM
Nov-20-25 03:00PM
Nov-13-25 09:15AM
08:00AM
Nov-10-25 09:15AM
07:00AM
06:25PM Loading…
Nov-06-25 06:25PM
Nov-05-25 05:35PM
10:00AM
Oct-22-25 08:18AM
Oct-07-25 08:00AM
Aug-14-25 09:10AM
08:35AM
08:00AM
Aug-07-25 08:45AM
Jun-27-25 08:03AM
May-13-25 04:30PM
09:15AM
08:00AM
May-09-25 08:00AM
Apr-10-25 09:49AM
11:50AM Loading…
Apr-01-25 11:50AM
Mar-25-25 10:50AM
09:21AM
Mar-18-25 03:29AM
Mar-14-25 08:27AM
Mar-13-25 08:05AM
08:00AM
07:30AM
Feb-24-25 07:30AM
Feb-21-25 06:30AM
Jan-22-25 08:30AM
Jan-20-25 03:25PM
Dec-29-24 06:19AM
Dec-10-24 09:38AM
Dec-09-24 08:00AM
Nov-24-24 07:27PM
Nov-13-24 09:15AM
08:00AM
Oct-22-24 08:00AM
Oct-16-24 04:43PM
07:30AM
06:45AM
Oct-15-24 12:13PM
07:00AM
Oct-09-24 04:30PM
Aug-30-24 09:46AM
Aug-12-24 07:40AM
07:05AM
07:03AM
May-24-24 09:57AM
May-22-24 09:32AM
May-10-24 03:09PM
May-09-24 01:53PM
08:00AM
Apr-24-24 04:30PM
Apr-18-24 04:30PM
Mar-14-24 10:31AM
09:45AM
08:30AM
Feb-13-24 08:00AM
Feb-01-24 07:30AM
Jan-10-24 09:55AM
08:49AM
Jan-02-24 12:17PM
Dec-25-23 09:55AM
Dec-21-23 07:07AM
07:00AM
Nov-21-23 04:30PM
Nov-14-23 07:21PM
08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:25AM
07:30AM
Oct-24-23 08:30AM
Aug-10-23 09:15AM
08:00AM
Aug-01-23 09:10AM
Jul-19-23 08:30AM
Jun-28-23 07:53PM
Jun-27-23 03:41PM
07:30AM
Jun-22-23 04:01PM
Jun-16-23 10:00AM
Jun-02-23 09:55AM
May-17-23 09:55AM
May-16-23 09:00AM
May-11-23 08:00AM
May-03-23 08:30AM
Apr-21-23 08:30AM
Apr-20-23 05:00PM
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giroux RichardCFO & COOApr 21 '26Sale10.2256,000572,320971,530Apr 21 09:01 PM
Richard GirouxOfficerApr 21 '26Proposed Sale10.2256,000572,545Apr 21 08:59 PM
Naylor StuartCHIEF DEV. OFFICERApr 07 '26Sale9.3627,661258,907668,505Apr 07 08:57 PM
Naylor StuartOfficerApr 07 '26Proposed Sale9.3627,661258,875Apr 07 04:17 PM
Forbes AlexandriaPRESIDENT & CEOMar 24 '26Sale7.4162,000459,4201,449,695Mar 24 09:12 PM
Alexandria ForbesOfficerMar 24 '26Proposed Sale7.4162,000459,420Mar 24 09:11 PM
Giroux RichardCFO & COOOct 21 '25Sale8.8724,000212,880829,494Oct 21 09:19 PM
Richard GirouxOfficerOct 21 '25Proposed Sale8.8724,000212,880Oct 21 09:17 PM
Forbes AlexandriaPRESIDENT & CEOOct 07 '25Sale8.3947,500398,5251,313,983Oct 07 09:49 PM
Alexandria ForbesOfficerOct 07 '25Proposed Sale8.3947,500398,525Oct 07 09:47 PM
Giroux RichardCFO & COOJul 22 '25Sale8.5224,000204,480853,494Jul 22 09:01 PM
Richard GirouxOfficerJul 22 '25Proposed Sale8.5224,000204,480Jul 22 08:58 PM
Forbes AlexandriaPRESIDENT & CEOJul 08 '25Sale7.9747,500378,5751,361,483Jul 08 08:57 PM
Alexandria ForbesOfficerJul 08 '25Proposed Sale7.9747,500378,575Jul 08 08:55 PM